Quantcast

Latest Angina pectoris Stories

2014-09-15 12:26:57

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device used in the heart that functions like a stent but dissolves over time ABBOTT PARK, Ill., Sept. 15, 2014 /PRNewswire/ -- Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the...

2014-09-14 20:20:15

Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND OAKS, Calif., Sept. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18(th)...

2014-09-14 12:20:52

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time WASHINGTON, Sept. 14, 2014 /PRNewswire/ -- Abbott announced today positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family of DES. The trial,...

heart thinkstock 452128839
2014-08-20 03:30:48

American Heart Association Rapid Access Journal Report U.S. hospitalizations and deaths from heart disease and stroke dropped significantly in the last decade, according to new research in the American Heart Association journal Circulation. “Interestingly, these improvements happened in a period when there were no real ‘miracle’ clinical advancements,” said Harlan Krumholz, M.D., S.M., lead author of the “most comprehensive report card to-date” on America’s progress in...

2014-08-13 08:26:49

SAN DIEGO, Aug. 13, 2014 /PRNewswire/ -- Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional...

2014-07-23 23:26:50

EECP Treatment is FDA-Cleared for Refractory Angina and Offered at Dr. Weaver’s EECP Independent Outpatient Facility in the U.S. Los Angeles, CA (PRWEB) July 22, 2014 Ronald S. Weaver, MD, owner of Global Cardio Care Centers in Inglewood, Calif., today announced a heart transplant patient with cardiomyopathy has successfully completed a course of Enhanced External Counterpulsation (EECP) therapy at Global Cardio Care Centers and is no longer a candidate for heart transplant. The...

2014-07-14 23:02:45

ReportsnReports.com adds “EpiCast Report Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022” to its store. The majority of the cases occurred in men (58.15%) and in those ages 65 years (69.34%). Dallas, TX (PRWEB) July 14, 2014 Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will...

2014-06-24 08:32:14

Pioneering Angiogenic Gene Therapy for the Potential Treatment of Millions of Patients with Heart Disease Worldwide SAN DIEGO, June 24, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(®) Ad5FGF-4, Cardium Therapeutics' angiogenic gene...

2014-05-19 08:27:47

-Addition of product to Specialty Pharmaceuticals portfolio expected to be immediately accretive to adjusted diluted earnings per share DUBLIN, May 19, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel(®) DosePro(®) (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash...

2014-04-24 08:33:37

-- Addition of product to Specialty Pharmaceuticals portfolio expected to be immediately accretive to adjusted diluted earnings per share DUBLIN, April 24, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that affiliates of the company have acquired worldwide rights to Sumavel(®) DosePro(®) (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. Under the terms of the agreement, Endo...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related